Updates on Endometrial Cancer Screening and Treatment

Dear Colleagues,

Endometrial cancer is a type of cancer that originates in the inner lining of the uterus, known as the endometrium. It is the most common gynecologic cancer in developed countries and primarily affects postmenopausal women, although it can occur in premenopausal women as well. In 2020, 417,367 new cases of endometrial cancer were registered, with up to 14% of them were in patients of reproductive age. Endometrial cancer often presents with noticeable symptoms, prompting women to seek medical attention. The most common symptom is abnormal vaginal bleeding, particularly postmenopausal bleeding. Other symptoms may include pelvic pain, pain during intercourse and unexplained weight loss.

Endometrial cancer is a heterogeneous disease with multiple etiological factors contributing to its development. The most prominent risk factor is a hormonal imbalance, specifically an increased exposure to estrogen unopposed by progesterone. This hormonal imbalance can result from various conditions, including obesity, metabolic syndrome and hormone replacement therapy. Nulliparity, early menarche, late menopause, tamoxifen use, older age and Lynch syndrome are also among the risk factors. Understanding the molecular mechanisms underlying endometrial cancer development, such as alterations in the PTEN/PI3K/Akt pathway and DNA mismatch repair genes, is essential for targeted therapeutic interventions and estimating the risk of recurrence and survival.

In this Special Issue, we present an update regarding the diagnosis and screening of endometrial cancer, the role of molecular features of endometrial carcinoma in overall survival and the latest data concerning treatment options.

We are pleased to invite authors to submit manuscripts focusing on the screening, diagnosis, management and treatment of endometrial cancer, and we are soliciting original studies, meta-analysis, reviews and case report investigating new advances in endometrial cancer treatment.

Dr. Dimitrios Papageorgiou
Dr. Dimitrios-Efthymios Vlachos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• endometrial cancer
• endometrial intraepithelial neoplasia
• microsatellite instability
• mismatch repair
• hysterectomy
• chemotherapy
• radiation therapy
• hormonal therapy